Bifidobacterium angulatum

Bacteria
General | Carbohydrate O/F | Substrate utilisation | Enzymes | Metabolites | Antibiotics

Overview

  • Bifidobacterium angulatum is a Gram-positive, non-spore-forming, strictly anaerobic, non-motile, rod-shaped bacterium. It has been detected in at least 15 gut microbiome compilation studies or metastudies. The DNA G+C content is 59.0%. Bifidobacterium angulatum is a common gut coloniser. (Scardovi1974)



  • This organism has been recovered from human faeces. The risk classification (www.baua.de) for this organism is 1, i.e., low risk of infection and spread. Pathogenicity status unknown, or very unlikely to be pathogenic. Is a known gut commensal.
    • GENERAL CHARACTERISTICS (Scardovi1974);
    Character Response
  • Substrates hydrolysed or digested:
  • aesculin;
  • ±
  • Strain-dependent hydrolysis or digestion:
  • milk;
  • pH
  • Acidity tolerance:
  • doesn't tolerate pH 8; Grows optimally at pH 6.5-6.9.
  • 🌡
  • Temperature tolerance:
  • grows at 28℃; grows at 42℃; Grows optimally at 39℃.
  • H+
  • Acid from carbohydrates usually produced:
  • L-arabinose; fructose; galactose; glucose; ribose; xylose; starch; gentiobiose; lactose; maltose; melibiose; raffinose; sucrose; D-turanose;
  • ⥅
  • Substrates assimilated or utilised:
  • melibiose;
  • Active enzymes:
  • α-galactosidase; β-galactosidase; α-glucosidase; β-glucosidase;
    • SPECIAL FEATURES (Scardovi1974);
    Character Response
  • ✓
  • Metabolites produced:
  • acetate; lactate;
  • ✗
  • Metabolites not produced:
  • indole;
  • ✗
  • VP test:
  • not active
  • ✗
  • Nitrate:
  • not reduced
    • RESPONSE TO ANTIBIOTICS (Matteuzzi1983); (Goldstein2013); (Goldstein2013a);
    Class Active Resistant
  • Penicillins:
  • amoxicillin; amoxicillin-clavulanic acid; cloxacillin; imipenem; oxacillin; penicillin G; piperacillin; piperacillin-tazobactam; ticarcillin;
  • Cephalosporins:
  • cefotaxime; cefotetan; cefoxitin; cephalothin;
  • Macrolides:
  • erythromycin; fidaxomicin; pristinamycin; spiramycin; telithromycin;
  • Tetracyclines:
  • minocycline;
  • Quinolines:
  • ciprofloxacin; gatifloxacin; ofloxacin;
  • nalidixic-acid;
  • Aminoglycosides:
  • gentamicin; kanamycin; neomycin; streptomycin;
  • Polypep/ketides:
  • bacitracin; rifampicin;
  • Heterocycles:
  • chloramphenicol; nitrofurantoin;
  • Vancomycins:
  • vancomycin; teicoplanin;
  • Miscellaneous antibiotics:
  • lincomycin; pristinamycin; telithromycin;
  • polymyxin B;

  • Scardovi, V., & Crociani, F. (1974). Bifidobacterium catenulatum, Bifidobacterium dentium, and Bifidobacterium angulatum: Three New Species and Their Deoxyribonucleic Acid Homology Relationships. International Journal of Systematic Bacteriology, 24(2), 310–310.

    • Details

    GENERAL
    Lineage Physiology General Growth Tolerances Hydrol./digest./degr.
    Phylum:  Actinobacteria Class:  Actinomycetia Order:  Bifidobacteriales Family:  Bifidobacteriaceae Genus:  Bifidobacterium Gram stain:  + O2 Relation.:  strictly anaerobic Spore:  No spore Motility:  Sessile Morphology:  Rod
    Health:  Unknown
    Source:  human faeces
    DNA G+C(%):  59.0
    Opt. T:  39℃
    Lower T(℃):  28(+)
    High T(℃):  42(+)
    Opt. pH:  6.5-6.9
    pH 6.0-8.0:  8(neg)
    		Aesculin:  + Urea:  neg Gelatin:  neg Arginine:  neg Hippurate:  neg Milk:  curdle
    CARBOHYDRATE ACID FORMATION
    Monosaccharide O/F Oligosaccharide O/F Polysaccharide O/F Polyol O/F Other O/F
    D-Arabinose:  neg L-Arabinose:  + Fructose:  + Fucose:  neg D-Fucose:  neg Galactose:  + Glucose:  + Mannose:  neg D-Lyxose:  neg Rhamnose:  neg Ribose:  + Sorbose:  neg D-Tagatose:  neg Xylose:  + L-Xylose:  neg Cellubiose:  neg Gentiobiose:  + Lactose:  + Maltose:  + Melezitose:  neg Melibiose:  + Sucrose:  + Turanose:  + Amygdalin:  vr Dextrin:  neg Glycogen:  neg Inulin:  vr Starch:  + Adonitol:  neg D-Arabitol:  neg L-Arabitol:  neg Dulcitol:  neg Erythritol:  neg Glycerol:  neg Inositol:  neg Mannitol:  neg Sorbitol:  neg Xylitol:  neg Arbutin:  vr Gluconate:  neg 2-Ketogluconate:  neg 5-Ketogluconate:  neg Me-α-D-Glc:  vr Me-α-D-Mann:  neg Me-Xyloside:  neg NAc-α-GA:  neg Salicin:  vr
    SUBSTRATE ASSIMILATION & UTILISATION
    Monosaccharide util/assim Oligosaccharide util/assim Other carboh. util/assim Amino acid util/assim Organic acid util/assim
    Melibiose:  +
    ENZYME ACTIVITY
    Enzymes: General Enzymes: Carbohydrate Enzymes: Protein Enzymes: Arylamidases Enzymes: Esters/fats
    Oxidase:  neg Catalase:  neg Urease:  neg Ac-β-glcamnd:  neg α-Fucosidase:  neg α-Galactosidase:  + β-Galactosidase:  + α-Glucosidase:  + β-Glucosidase:  + β-Glucuronidase:  neg β-Mannosidase:  neg ArgDH:  neg GluDC:  neg AlanineAA:  neg AlaPheProAA:  neg GluGluAA:  neg GlyAA:  neg LeuAA:  neg LeuGlyAA:  neg PyrrolidAA:  neg AlkalineP:  neg
    METABOLITES - PRODUCTION & USE
    Fuel Usable Metabolites Metabolites Released Special Products Compounds Produced

    		Acetate:  + Lactate:  + Indole:  neg
    ANTIBIOTICS ℞
    Penicillins & Penems (μg/mL) Cephalosporins (μg/mL) Aminoglycosides (μg/mL) Macrolides (μg/mL) Quinolones (μg/mL)
    amoxicillin:  Sens
    Augmentin:  Sens
    cloxacillin:  Sens
    oxacillin:  Sens
    penicillin_G:  S(MIC50): 0.18, MIC90: 0.28, RNG: (0.1-0.3)
    piperacillin:  Sens
    piper-taz:  S(MIC50): 0.06, MIC90: 1, RNG: (0.015–2)
    ticarcillin:  Sens
    imipenem:  S(MIC50): 0.06, MIC90: 0.5, RNG: (0.015–2)
    cefotaxime:  Sens
    cefotetan:  Sens
    cefoxitin:  Sens
    cephalothin:  Sens
    gentamicin:  Res
    kanamycin:  R(>300)
    neomycin:  R(MIC50): <150, MIC90: 184, (150-200)
    streptomycin:  R(MIC50): 192, MIC90: 1053, RNG: (50-1500)
    erythromycin:  S(MIC50): 0.2, MIC90: 0.44, RNG: 0.05-0.5)
    fidaxomicin:  S(MIC50): 0.125, MIC90: 0.125, RNG: (0.03–0.25)
    pristinamycin:  Sens
    spiramycin:  Sens
    telithromycin:  Sens
    ciprofloxacin:  Sens
    gatifloxacin:  Sens
    moxifloxacin:  Var(MIC50): 1, MIC90: 8, RNG: (0.06–16)
    nalidixic-acid:  R(>200)
    ofloxacin:  Sens
    Tetracyclines (μg/mL) Vancomycin Class (μg/mL) Polypep/ketides (μg/mL) Heterocycles (μg/mL) Other (μg/mL)
    minocycline:  Sens
    tetracycline:  Var(MIC50): <1, MIC90: 79, RNG: (1-150)
    teicoplanin:  Sens
    vancomycin:  S(MIC50): 1, MIC90: 1, RNG: (0.5–1)
    bacitracin:  S(MIC50): <0.05, MIC90: 0.15, RNG: (0.05-0.2)
    rifampicin:  Sens
    chloramphenicol:  S(MIC50): 1.7, MIC90: 2.8, RNG: (1-3)
    metronidazole:  Var(MIC50): 16, MIC90: >32, RNG: (0.5–>32)
    nitrofurantoin:  S(MIC50): 17, MIC90: 25, RNG: (15-30)
    lincomycin:  Sens
    polymyxin_B:  R(>700)

    References

    SPECIFIC REFERENCES FOR BIFIDOBACTERIUM ANGULATUM
  • Matteuzzi1983 - Antimicrobial susceptibility of Bifidobacterium.
  • Scardovi1974 - Bifidobacterium catenulatum, Bifidobacterium dentium, and Bifidobacterium angulatum: Three New Species and Their Deoxyribonucleic Acid Homology Relationships.
  • Finegold2010 - Pyrosequencing study of fecal microflora of autistic and control children
  • Moore1995 - Intestinal floras of populations that have a high risk of colon cancer
  • Tarallo2019 - Altered Fecal Small RNA Profiles in Colorectal Cancer Reflect Gut Microbiome Composition in Stool Samples
  • Goldstein2013 - In vitro activity of Biapenem plus RPX7009, a carbapenem combined with a serine β-lactamase inhibitor, against anaerobic bacteria.
  • Goldstein2013a - Comparative in vitro activities of SMT19969, a new antimicrobial agent, against Clostridium difficile and 350 gram-positive and gram-negative aerobic and anaerobic intestinal flora isolates.
  • ...............................
    • GUT MICROBIOME COMPILATIONS AND METASTUDIES FOR BIFIDOBACTERIUM ANGULATUM
  • Byrd2020 - Stability and dynamics of the human gut microbiome and its association with systemic immune traits.
  • De2020 - Metagenomic analysis of gut microbiome and resistome of diarrheal fecal samples from Kolkata, India, reveals the core and variable microbiota including signatures of microbial dark matter.
  • Dubinkina2017 - Links of gut microbiota composition with alcohol dependence syndrome and alcoholic liver disease
  • Forster2019 - A human gut bacterial genome and culture collection for improved metagenomic analyses.
  • Jie2017 - The gut microbiome in atherosclerotic cardiovascular disease
  • Lagier2016 - Culture of previously uncultured members of the human gut microbiota by culturomics.
  • MacFarlane2004 - Chemotaxonomic analysis of bacterial populations colonizing the rectal mucosa in patients with ulcerative colitis.
  • Moore1995 - Intestinal floras of populations that have a high risk of colon cancer
  • New2022 - Collective effects of human genomic variation on microbiome function.
  • RajilicStojanovic2014 - The first 1000 cultured species of the human gastrointestinal microbiota.
  • Rothschild2018 - Environment dominates over host genetics in shaping human gut microbiota.
  • Tyakht2013 - Human gut microbiota community structures in urban and rural populations in Russia.
  • Woodmansey2004 - Comparison of compositions and metabolic activities of fecal microbiotas in young adults and in antibiotic-treated and non-antibiotic-treated elderly subjects.
  • Zeller2014 - Potential of fecal microbiota for early-stage detection of colorectal cancer
  • ...............................
    • GENERAL REFERENCES FOR BIFIDOBACTERIUM ANGULATUM
  • CCUG - Culture Collection University of Gothenburg - Entire Collection
    • Added: April 08, 2021